BioCentury | Aug 13, 2020
Emerging Company Profile

RA-incubated Aerovate to deploy $72.6M series A for inhaled imatinib for PAH

...trial is starting imminently,” said Dake, with a registrational trial of AV-101 to begin in 1H21.Aerami Therapeutics Holdings Inc....
...57148B, Ruvise, STI-571) Aerovate Therapeutics Inc. Sofinnova Investments Inc. Atlas Venture Cormorant Asset Management Surveyor Capital Osage University Partners RA Capital Management Novartis AG Aerami Therapeutics Holdings Inc....
BioCentury | Sep 26, 2018
Company News

Management tracks: Merck clears path for Frazier to remain CEO

...president, CEO and a director. He replaces Glenn Nedwin, who retired. Inhaled diabetes therapy company Dance Biopharm...
BioCentury | Mar 2, 2015
Financial News

Dance Biopharm completes venture financing

Dance Biopharm Inc. , Brisbane, Calif. Business: Endocrine/Metabolic Date completed: 2015-02-18 Type: Venture financing Raised: $9.5 million Placement agent: SternAegis Ventures Investors: Individual investors; institutional investors Note: The offering was comprised of convertible notes and warrants....
BioCentury | Oct 20, 2014
Financial News

Dance Biopharm withdraws IPO

Dance Biopharm Inc. , Brisbane, Calif. Business: Endocrine/Metabolic Date announced: 2014-10-15 Type: IPO Underwriters: Wells Fargo; Stifel, Nicolaus & Co.; Oppenheimer; Roth Capital Partners Note: The company withdrew its proposed IPO on NASDAQ but did not...
BioCentury | Oct 17, 2014
Financial News

Dance withdraws IPO

Dance Biopharm Inc. (Brisbane, Calif.) withdrew its proposed IPO on NASDAQ. The diabetes company did not provide a reason in its SEC filing. In April, the company filed to raise up to $75 million in...
BioCentury | Oct 6, 2014
Finance

4Q14 Financial Markets Preview: 'Perfect world' - for now

...NYSE-M) (H) 4/16/14 Up to $28.8M Ph III Angion Biomedica Corp. 4/14/14 $30M Ph II Dance Biopharm...
BioCentury | Jul 14, 2014
Finance

3Q14 Financial Markets Preview: Discerning optimism

...NYSE-M) (E) 4/16/14 Up to $28.8M Ph III Angion Biomedica Corp. 4/14/14 $30M Ph II Dance Biopharm...
BioCentury | Apr 14, 2014
Financial News

Dance Biopharm proposes IPO

Dance Biopharm Inc. , Brisbane, Calif. Business: Endocrine/Metabolic Date announced: 4/9/14 Type: IPO To be raised: Up to $75 million Shares: TBD Price: TBD Underwriters: Wells Fargo; Stifel, Nicolaus; Oppenheimer; Roth Capital Partners Note: The company...
BioCentury | Apr 10, 2014
Financial News

Inhalable insulin play Dance files for IPO

Dance Biopharm Inc. (Brisbane, Calif.) filed to raise up to $75 million in an IPO on NASDAQ underwritten by Wells Fargo; Stifel; Oppenheimer; and Roth Capital Partners. Dance is developing Dance 501 (formerly Adagio ),...
BioCentury | Oct 21, 2013
Company News

Dance Biopharm, Harmony Asset deal

...Samba 01 trial evaluating Adagio in Type I diabetics. The partners declined to disclose details. Dance Biopharm...
Items per page:
1 - 10 of 11
BioCentury | Aug 13, 2020
Emerging Company Profile

RA-incubated Aerovate to deploy $72.6M series A for inhaled imatinib for PAH

...trial is starting imminently,” said Dake, with a registrational trial of AV-101 to begin in 1H21.Aerami Therapeutics Holdings Inc....
...57148B, Ruvise, STI-571) Aerovate Therapeutics Inc. Sofinnova Investments Inc. Atlas Venture Cormorant Asset Management Surveyor Capital Osage University Partners RA Capital Management Novartis AG Aerami Therapeutics Holdings Inc....
BioCentury | Sep 26, 2018
Company News

Management tracks: Merck clears path for Frazier to remain CEO

...president, CEO and a director. He replaces Glenn Nedwin, who retired. Inhaled diabetes therapy company Dance Biopharm...
BioCentury | Mar 2, 2015
Financial News

Dance Biopharm completes venture financing

Dance Biopharm Inc. , Brisbane, Calif. Business: Endocrine/Metabolic Date completed: 2015-02-18 Type: Venture financing Raised: $9.5 million Placement agent: SternAegis Ventures Investors: Individual investors; institutional investors Note: The offering was comprised of convertible notes and warrants....
BioCentury | Oct 20, 2014
Financial News

Dance Biopharm withdraws IPO

Dance Biopharm Inc. , Brisbane, Calif. Business: Endocrine/Metabolic Date announced: 2014-10-15 Type: IPO Underwriters: Wells Fargo; Stifel, Nicolaus & Co.; Oppenheimer; Roth Capital Partners Note: The company withdrew its proposed IPO on NASDAQ but did not...
BioCentury | Oct 17, 2014
Financial News

Dance withdraws IPO

Dance Biopharm Inc. (Brisbane, Calif.) withdrew its proposed IPO on NASDAQ. The diabetes company did not provide a reason in its SEC filing. In April, the company filed to raise up to $75 million in...
BioCentury | Oct 6, 2014
Finance

4Q14 Financial Markets Preview: 'Perfect world' - for now

...NYSE-M) (H) 4/16/14 Up to $28.8M Ph III Angion Biomedica Corp. 4/14/14 $30M Ph II Dance Biopharm...
BioCentury | Jul 14, 2014
Finance

3Q14 Financial Markets Preview: Discerning optimism

...NYSE-M) (E) 4/16/14 Up to $28.8M Ph III Angion Biomedica Corp. 4/14/14 $30M Ph II Dance Biopharm...
BioCentury | Apr 14, 2014
Financial News

Dance Biopharm proposes IPO

Dance Biopharm Inc. , Brisbane, Calif. Business: Endocrine/Metabolic Date announced: 4/9/14 Type: IPO To be raised: Up to $75 million Shares: TBD Price: TBD Underwriters: Wells Fargo; Stifel, Nicolaus; Oppenheimer; Roth Capital Partners Note: The company...
BioCentury | Apr 10, 2014
Financial News

Inhalable insulin play Dance files for IPO

Dance Biopharm Inc. (Brisbane, Calif.) filed to raise up to $75 million in an IPO on NASDAQ underwritten by Wells Fargo; Stifel; Oppenheimer; and Roth Capital Partners. Dance is developing Dance 501 (formerly Adagio ),...
BioCentury | Oct 21, 2013
Company News

Dance Biopharm, Harmony Asset deal

...Samba 01 trial evaluating Adagio in Type I diabetics. The partners declined to disclose details. Dance Biopharm...
Items per page:
1 - 10 of 11